Filter by: patients
Home > Community Treatment Reports and Side Effects > Lenalidomide Treatment Report
What is Lenalidomide?

Lenalidomide is an anticancer agent available under the brand name Revlimid®. It is used in the treatment of myelodysplastic syndrome (MDS) in patients with deletion 5q cytogenetic abnormality and for treatment of multiple myeloma. Off label used for metastatic malignant melanoma and myelofibrosis.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Multiple Myeloma 2 1 Efficacy_moderate

See 1 patient currently taking Lenalidomide

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 1
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Lenalidomide

Fatigue 1
Tiredness 1
Hospitalization 1

Reported Dosages

  25 mg daily
  1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Lenalidomide (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking Lenalidomide

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Lenalidomide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Lenalidomide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Lenalidomide

Always
 0 0%
Usually
 1 100%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Lenalidomide

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Lenalidomide

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.